CADL
Candel Therapeutics, Inc.
$9.64
-0.23 (-2.33%)
At close · Jul 15
Market Cap
$694.60M
Shares
73,270,239
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$125K
0%
FY2022
Net Income
-$38.18M
+30.8%
FY2025
Operating Margin
-27777.6%
-7196.8pp
FY2022
Diluted EPS
-$0.72
+58.6%
FY2025
Operating Cash Flow
-$38.31M
-41.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| — | — | — | — | $125K | $125K | $125K | |
| $36.32M | $30.5M | $19.31M | $24.51M | $20.79M | $15.18M | $8.75M | |
| $20.1M | $17.77M | $14.06M | $13.89M | $14.06M | $10.67M | $5.18M | |
| $843K | — | — | — | $778K | $232K | $91K | |
| $56.42M | $48.27M | $33.37M | $38.39M | $34.85M | $25.85M | $13.94M | |
| -$56.42M | -$48.27M | -$33.37M | -$38.39M | -$34.72M | -$25.73M | -$13.81M | |
| — | — | — | — | -27777.6% | -20580.8% | -11048% | |
| -$35.35M | — | — | — | -$33.94M | -$25.49M | -$13.72M | |
| $3.38M | $2.12M | $2.09M | -$2.6M | $1.71M | — | — | |
| $1.48M | — | — | $2.08M | $1.22M | — | — | |
| $2M | $10.08M | -$21.81M | $452K | $15.93M | -$10.4M | -$3.87M | |
| — | -$38.18M | -$55.18M | — | — | — | — | |
| — | $0 | $0 | $0 | $0 | $0 | — | |
| -$54.42M | -$38.18M | -$55.18M | -$37.94M | -$18.79M | -$36.12M | -$17.68M | |
| — | — | — | — | -15035.2% | -28899.2% | -14144% | |
| — | — | — | — | — | -$36.12M | -$17.66M | |
| USD/shares | — | -$0.72 | -$1.74 | -$1.31 | -$0.65 | -$1.91 | — |
| USD/shares | — | -$0.72 | -$1.74 | -$1.31 | -$0.65 | -$1.91 | — |
| shares | — | 52.96M | 31.68M | 28.94M | 28.82M | 18.87M | 11.62M |
| shares | — | 52.96M | 31.68M | 28.94M | 28.82M | 18.87M | 11.62M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.53×
EV/EBIT
—
Biotechnology median 26.49×
P/E (TTM)
—
Biotechnology median 7.39×